At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
During the combined meeting of the 46th Malaysian Orthopaedic Association Annual General Meeting/Annual Scientific Meeting and the 10th ASEAN Arthroplasty Association Meeting, Dr Joseph Pergolizzi spoke on the importance of chronic pain control and appropriate strategies to achieve this. Highlights of his presentation are summarized below.
Calcium and vitamin D play a major role in the prevention and treatment of osteoporosis. In this exclusive interview with MIMS Doctor, Dr Yeap Swan Sim talks about the importance of calcium and vitamin D in bone health, as well as the current status of these micronutrients in local postmenopausal women.
Recently, MIMS Doctor sat down with Associate Professor Dr Sabarul Afian Mokhtar to get his perspectives on the use of monoclonal antibody for the treatment of postmenopausal osteoporosis (PO) and also important learning from the International Osteoporosis Foundation (IOF) Regionals 5th Asia-Pacific Osteoporosis Meeting. Highlights from the interview are presented here.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.
Concomitant statin therapy was associated with an attenuation of tocilizumab (TCZ)-mediated increase in serum lipids in patients with rheumatoid arthritis (RA), according to a recent post hoc analysis of randomized clinical studies.
Patients with early rheumatoid arthritis (RA) may benefit from the initial addition of certolizumab pegol (CZP) to optimized methotrexate (MTX) therapy, as this strategy potentially prevents joint destruction, according to the results of the phase III C-OPERA* study.
The addition of prednisone to methotrexate (MTX)-based treat-to-target strategy for early rheumatoid arthritis (RA) leads to a lower initiation rate of a first biological disease-modifying antirheumatic drug and a significant improvement in radiographic outcomes, a study has shown. Furthermore, prednisone use does not increase the incidence of long-term glucocorticoid-related comorbidities.
Fidaxomicin shows potential for treating Clostridium difficile infection (CDI), with response and recurrence being significantly better in patients with a first CDI episode than in those with prior episodes, according to data from an open-label study.